# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains ...
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(...
B. Riley Securities analyst Kalpit Patel downgrades X4 Pharmaceuticals (NASDAQ:XFOR) from Buy to Neutral and lowers the pric...
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...